Novartis India Q1 FY27 Results (NSE: NOVARTIND)

· Analysis by Alpha Inflection

Signal: Margin expansion

The read

Q1FY27 standalone results show strong double-digit revenue growth (+18.6% YoY) and even stronger PAT growth (+16.6% YoY), supported by operating leverage from declining employee costs (-10.8% YoY) and well-controlled other expenses (+2.4% YoY). Gross margins held steady (~46.4%), and the company remains debt-free with negligible finance costs. The only minor drag is lower other income (-17.7% YoY). Earnings quality is clean — no exceptional items, no dilution, and PAT/EPS move in lockstep. The open-offer tendering narrative (negligible tenders reported in June 2026) does not affect operating performance.

Novartis India Q1 FY27 key financials
MetricValueYoYQoQ
Revenue₹103.81 Cr18.57%14.64%
EBIT₹43.11 Cr16.14%
Net profit₹32.21 Cr16.62%
EPS₹13.0516.62%
EBIT margin41.57%

P&L walk

Standalone-only filer — no consolidated statement. Revenue rose 18.6% YoY to ₹1,038.1mn, driven by higher stock-in-trade purchases (net ₹556.7mn, +19.1%) consistent with in-licensed model; gross margin (revenue less net purchases) as % of revenue improved to 46.4% vs 46.2% a year ago (stable, ~20bps expansion). Employee costs declined 10.8% YoY as a % of revenue (4.5% vs 6.0%), providing operating leverage; other expenses rose just 2.4% YoY, well below revenue growth. EBITDA margin (PBT + finance cost + depreciation) at ~42.0% (implied EBITDA ₹435.9mn) expanded ~120bps YoY. PBT grew 16.0% despite lower other income (-17.7%). Tax rate 25.4% vs 25.8% YoY. PAT ₹322.1mn, +16.6% YoY; EPS ₹13.05 tracked PAT exactly. No segment data reported; pure domestic formulations.

Key positives

Key concerns

View original filing

Research and educational content only. Not investment advice.